Raltegravir Therapy for Women With HIV and Fat Accumulation

Phase II Study of Raltegravir as Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Based Antiretroviral Therapy in Women With Fat Accumulation

Ritonavir-boosted protease inhibitor (PI) regimens have become a backbone for treatment of people with HIV. However, adverse drug effects, particularly lipodystrophy/lipoatrophy are closely associated with these regimens. Therefore, there is a need for a drug with comparable effectiveness to the ritonavir boosted PIs without the side effects of dyslipidemia, which has been associated with elevated cholesterol and cardiovascular disease

Raltegravir is an HIV integrase inhibitor in phase III clinical development. To date there are no approved drugs that target the same stage of the HIV-1 lifecycle. However, data from studies indicate that raltegravir is generally safe and well tolerated and has strong antiretroviral activity when used in combination with licensed antiretroviral medications.

This study aims to demonstrate that patients substituting raltegravir for a PI or NNRTI based antiretroviral regimen will be associated with a 10% reduction in body fat over 24 weeks.

The study will consist of a total of 10 subject visits over a period of 48 weeks. Approximately 40 female patients will participate in this study (approximately 10 at UCLA).

Study Overview

• Status: Completed
• Conditions: HIV Infections; Lipodystrophy
• Intervention / Treatment: Drug: raltegravir

• Study Type: Interventional
• Enrollment (Actual): 39
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada
      • University Health Network, Toronto
• United States
  • California
    • Los Angeles, California, United States, 90035
      • UCLA CARE Center
  • Massachusetts
    • Boston, Massachusetts, United States, 02111
      • Tufts University School of Medicine
  • Ohio
    • Cleveland, Ohio, United States, 44106
      • Case School of Medicine
  • Tennessee
    • Nashville, Tennessee, United States, 37203
      • Vanderbilt University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• HIV-1 infection as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry or plasma HIV-1 RNA > 2000 on two occasions,
• Female subjects 18 years or older
• Documented central fat accumulation (defined by waist circumference of > 94 cm or a waist to hip ratio of > 0.88).
• Documented HIV RNA <50 copies/mL at screening and <400 copies/mL in the past 6 months.
• Current antiretroviral therapy with two nucleoside analogues and either a non-nucleoside analogue (nevirapine, efavirenz or TMC125) or an approved protease inhibitor. Patients on NNRTI+PI at study entry will be excluded. Study participants do not need to be on their first regimen. No changes in ART in the 12 weeks prior to screening. The nucleoside backbone must include either tenofovir or abacavir and either lamivudine or emtricitabine. Fixed dose combinations with emtricitabine or abacavir are allowed.
• For females of reproductive potential (women who have not been post-menopausal for at least 24 consecutive months, i.e., who have had menses within the preceding 24 months, or women who have not undergone surgical sterilization, specifically hysterectomy, or bilateral oophorectomy and/or tubal ligation), will need a negative serum or urine pregnancy test within 48 hours prior to entry.
• Ability and willingness of subject to provide informed consent.

Exclusion Criteria:

• Pregnancy: current or within the past 6 months or breast feeding
• Prior treatment history that would preclude the use of emtricitabine or abacavir as the nucleoside backbone during study treatment
• Current use of metformin or thiazolidinediones.
• Use of growth hormone or growth hormone releasing factor in the last 6 months before screening.
• Change or initiation of anti-hyperlipemic regimen within 3 months prior to randomization; Use of stable anti-hyperlipemic regimen during the study is allowed.
• Current use of androgen therapy.
• Intent to modify diet, exercise habits or to enroll in a weight loss intervention during the study period.
• Current or projected need to use rifampin, dilantin or phenobarbital during the 48-week study period.

• Laboratory values at screening of

  • ANC >500 cells/mm3
  • Hemoglobin <10 gm/dl
  • CrCl > 60 ml/min (estimated by Cockcroft-Gault equation)
  • AST or ALT > 3 x ULN

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Immediate; Immediate switch of PI or NNRTI to Raltegravir	Drug: raltegravir; raltegravir; Other Names: Isentress
Active Comparator: Delayed; Continue current therapy unchanged for 24 weeks, then switch PI or NNRTI to Raltegravir	Drug: raltegravir; raltegravir; Other Names: Isentress

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Baseline to 24-week Change in Visceral Adipose Tissue Volume (cm^2)	Adipose tissue volumes were measured via single slice L4-L5 CT scan, and volumes were calculated using cm^2, not cm^3, as is standard protocol at the Tufts University Body Composition Reading Center. The authors acknowledge that cm^2 uses area as a surrogate for volume, but this protocol is well-accepted in our field.	Baseline and 24 weeks

Collaborators and Investigators

• Sponsor: University of California, Los Angeles
• Collaborators: University Health Network, Toronto; Merck Sharp & Dohme LLC; Tufts University; Vanderbilt University; Case Western Reserve University
• Investigators: Principal Investigator: Judith S. Currier, M.D., University of California, Los Angeles; Study Chair: Grace McComsey, M.D., Case School of Medicine

Publications and helpful links

General Publications

• Lake JE, McComsey GA, Hulgan TM, Wanke CA, Mangili A, Walmsley SL, Boger MS, Turner RR, McCreath HE, Currier JS. A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDS. 2012 Sep;26(9):532-40. doi: 10.1089/apc.2012.0135. Epub 2012 Jul 23.
• Offor O, Utay N, Reynoso D, Somasunderam A, Currier J, Lake J. Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy. PLoS One. 2018 May 10;13(5):e0196395. doi: 10.1371/journal.pone.0196395. eCollection 2018.

Study record dates

Study Major Dates

• Study Start: September 1, 2008
• Primary Completion (Actual): December 1, 2011
• Study Completion (Actual): December 1, 2011

Study Registration Dates

• First Submitted: April 2, 2008
• First Submitted That Met QC Criteria: April 4, 2008
• First Posted (Estimate): April 10, 2008

Study Record Updates

• Last Update Posted (Estimate): December 19, 2012
• Last Update Submitted That Met QC Criteria: December 17, 2012
• Last Verified: December 1, 2012

More Information

Terms related to this study

• Keywords: HIV; treatment experienced; women; visceral fat; raltegravir; lipodystrophy; integrase inhibitor; fat; ART; Protease inhibitor; NNRTI; anti HIV therapy
• Additional Relevant MeSH Terms: Metabolic Diseases; Skin Diseases; Lipid Metabolism Disorders; Skin Diseases, Metabolic; Lipodystrophy; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Enzyme Inhibitors; Anti-HIV Agents; Anti-Retroviral Agents; HIV Integrase Inhibitors; Integrase Inhibitors; Raltegravir Potassium
• Other Study ID Numbers: IISP-Raltegravir